Management of endometrial hyperplasia

Minerva Ginecologica

Volumn 62, Issue 5, 2010, Pages 433-445

  Gultekin M ^a   Dogan, N U ^b   Aksan, G ^c   Ozgul, N ^a  

^a MINISTRY OF HEALTH   (Turkey)

^b Zekai Tahir Burak Maternity Teaching Hospital   (Turkey)

^c BASKENT UNIVERSITY   (Turkey)

Author keywords

Carcinoma in situ; Endometrial hyperplasia; Endometrium

Indexed keywords

AROMATASE INHIBITOR; DANAZOL; ESTROGEN; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; MICRONIZED PROGESTERONE; MIFEPRISTONE; NORETHISTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; TRIPTORELIN; UNCLASSIFIED DRUG;

CANCER RISK; CLINICAL FEATURE; CURETTAGE; DISEASE COURSE; DRUG MEGADOSE; ENDOMETRIUM ABLATION; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; INCIDENCE; LOW DRUG DOSE; POSTMENOPAUSE; PREMENOPAUSE; REVIEW;

DECISION TREES; ENDOMETRIAL HYPERPLASIA; FEMALE; HUMANS;

EID: 79251509260     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Montgomery BE, Daum GS, Dunton CJ. Endometrial hyperplasia: a review. Obstet Gynecol Surv 2004;59:368-78.
2. Soslow RA. Problems with the current diagnostic approach to complex atypical endometrial hyperplasia. Cancer 2006;106:729-31.
3. Gücer F, Reich O, Tamussino K, Bader AA, Pieber D, Schöll W et al. Concomitant endometrial hyperplasia in patients with endometrial carcinoma. Gynecol Oncol 1998;69:64-8. (Pubitemid 28201673)
4. Pickar JH, Archer DF. Is bleeding a predictor of endometrial hyperplasia in postmenopausal women receiving hormone replacement therapy? Menopause Study Group (United States, Italy, the Netherlands, Switzerland, Belgium, Germany, and Finland). Am J Obstet Gynecol 1997;177:1178-83.
5. Karamursel BS, Guven S, Tulunay G, Kucukali T, Ayhan A. Which surgical procedure for patients with atypical endometrial hyperplasia? Int J Gynecol Cancer 2005; 15:127-31.
6. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 1985;56:403-12.
7. Janicek MF, Rosenshein NB. Invasive endometrial cancer in uteri resected for atypical endometrial hyperplasia. Gynecol Oncol 1994;52:373-8.
8. Dunton CJ, Baak JP, Palazzo JP, van Diest PJ, McHugh M, Widra EA. Use of computerized morphometric analyses of endometrial hyperplasias in the prediction of coexistent cancer. Am J Obstet Gynecol 1996;174:1518-21. (Pubitemid 26165271)
9. Clark TJ, Neelakantan D, Gupta JK. The management of endometrial hyperplasia: an evaluation of current practice. Eur J Obstet Gynecol Reprod Biol 2006;125: 259-64.
10. Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ 2nd et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006;106.812-9.
11. Gültekin M, Diribafl K, Dursun P, Ayhan A. Current management of endometrial hyperplasia and endometrial intraepithelial neoplasia (EIN). Eur J Gynaecol Oncol 2009;30:396-401.
12. Cullen TS. Cancer of the uterus. New York, NY: D Appleton & Co; 1900.
13. Taylor HC Jr. Endometrial hyperplasia and carcinoma of the body of the uterus. Am J Obstet Gynecol 1932;23:309-32.
14. Ferenczy A, Gelfand MM, Tzipris F. The cytodynamics of endometrial hyperplasia and carcinoma. A review. Ann Pathol 1983;3:189-201.
15. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
16. Chan SS, Tam WH, Yeo W, Yu MM, Ng DP, Wong AW, Kwan WH, Yuen PM. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. BJOG 2007;114:1510-5. (Pubitemid 350077441)
17. Chin J, Konje JC, Hickey M. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst Rev 2009;(4):CD007245.
18. Reed SD, Newton KM, Clinton WL, Epplein M, Garcia R, Allison K et al. Incidence of endometrial hyperplasia. Am J Obstet Gynecol 2009;200:678.e1-6.
19. Gol K, Saracoglu F, Ekici A, Sahin I. Endometrial patterns and endocrinologic characteristics of asymptomatic menopausal women. Gynecol Endocrinol 2001;15:63-7.
20. Korhonen MO, Symons JP, Hyde BM, Rowan JP, Wilborn WH. Histologic classification and pathologic findings for endometrial biopsy specimens obtained from 2964 perimenopausal and postmenopausal women undergoing screening for continuous hormones as replacement therapy (CHART 2 Study). Am J Obstet Gynecol 1997;176:377-80.
21. Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG, Wilkinson EJ. Uterine corpus. Histological Typing of Female Genital Tract Tumors. New York, NY: Springer-Verlag; 1994. p. 13-31.
22. Diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma. Am J Surg Pathol 1998;22:1012-9.
23. Bergeron C, Nogales FF, Masseroli M, Abeler V, Duvillard P, Müller-Holzner E et al. A multicentric European study testing the reproducibility of the WHO Classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens. Am J Surg Pathol 1999;23: 1102-8.
24. Zaino RJ, Kauderer J, Trimble CL, Silverberg SG, Curtin JP, Lim PC et al. Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006;106:804-11. (Pubitemid 43238447)
25. Mutter GL. Histopathology of genetically defined endometrial precancers. Int J Gynecol Pathol 2000;19: 301-9.
26. Mutter GL, Baak JP, Crum CP, Richart RM, Ferenczy A, Faquin WC. Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry. J Pathol 2000;190:462-9.
27. Mutter GL. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group. Gynecol Oncol 2000;76:287-90.
28. Mutter GL, Zaino RJ, Baak JP, Bentley RC, Robboy SJ. Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia. Int J Gynecol Pathol 2007;26:103-14.
29. Mohan H, Baak JP. Morphometrical analysis in endometrial hyperplasia: predictive of progression to cancer. Indian J Pathol Microbiol 2006;49:21-2.
30. Orbo A, Baak JP, Kleivan I, Lysne S, Prytz PS, Broeckaert MA et al. Computerised morphometrical analysis in endometrial hyperplasia for the prediction of cancer development. A long-term retrospective study from northern Norway. J Clin Pathol 2000;53:697-703.
31. Baak JP, Mutter GL. EIN and WH094. J Clin Pathol 2005;58:1-6.
32. Baak JP, Ørbo A, van Diest PJ, Jiwa M, de Bruin P, Broeckaert M et al. Prospective multicenter evaluation of the morphometric D-score for prediction of the outcome of endometrial hyperplasias. Am J Surg Pathol 2001;25:930-5.
33. Baak JP. The role of computerized morphometric and cytometric feature analysis in endometrial hyperplasia and cancer prognosis. J Cell Biochem Suppl 1995;23:137-46.
34. Baak JP, Mutter GL, Robboy S, van Diest PJ, Uyterlinde AM, Orbo A et al. The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system. Cancer 2005;103:2304-12.
35. Mutter GL. Diagnosis of premalignant endometrial disease. J Clin Pathol 2002;55:326-31.
36. Hecht JL, Ince TA, Baak JP, Baker HE, Ogden MW, Mutter GL. Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis. Mod Pathol 2005;18:324-30.
37. Norimatsu Y, Shimizu K, Kobayashi TK, Moriya T, Tsukayama C, Miyake Y et al. Cellular features of endometrial hyperplasia and well differentiated adenocarcinoma using the Endocyte sampler: Diagnostic criteria based on the cytoarchitecture of tissue fragments. Cancer 2006;108:77-85.
38. Emoto M, Tamura R, Shirota K, Hachisuga T, Kawarabayashi T. Clinical usefulness of color Doppler ultrasound in patients with endometrial hyperplasia and carcinoma. Cancer 2002;94:700-6.
39. Karlsson B, Granberg S, Wikland M, Ylöstalo P, Torvid K, Marsal K et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding - Nordic multicenter study. Am J Obstet Gynecol 1995;172:1488-94.
40. Ferrazzi E, Torri V, Trio D, Zannoni E, Filiberto, S, Dordoni D. Sonographic endometrial thickness: a useful test to predict atrophy in patients with postmenopausal bleeding: an Italian multicenter study. Ultrasound Obstet Gynecol 1996;7:315-21.
41. Varner RE, Sparks JM, Cameron CD, Roberts LL, Soong SJ. Transvaginal sonography of the endometrium in postmenopausal women. Obstet Gynecol 1991;78:195.
42. Tabor A, Watt HC, Wald NT. Endometrial thickness as a test for endometrial cancer in women with postmenopausal vaginal bleeding. Obstet Gynecol 2002;99:663-70. (Pubitemid 34246309)
43. Gupta JK, Chien PF, Voit D, Clark TJ, Khan KS. Ultrasonographic endometrial thickness for diagnosing endometrial pathology in women with postmenopausal bleeding: a meta-analysis. Acta Obstet Gynecol Scand 2002;81:799-816.
44. Granberg S, Wikland M, Karlsson B, Norström A, Friberg LG. Endometrial thickness as measured by endo ultrasonography for identifying endometrial abnormality. Am J Obstet Gynecol 1991;164:47-52.
45. Goldstein SR. The role of transvaginal ultrasound or endometrial biopsy in the evaluation of the menopausal endometrium. Am J Obstet Gynecol 2009;201:5-11.
46. Wilailak S, Jirapinyo M, Theppisai U. Transvaginal Doppler sonography: is there a role for this modality in the evaluation of women with postmenopausal bleeding? Maturitas 2005;50:111-6.
47. Mercé LT, Alcázar JL, Engels V, Troyano J, Bau S, Bajo JM. Endometrial volume and vascularity measurements by transvaginal three-dimensionalultrasonography and power Doppler angiography in stimulated and tumoral endometria: intraobserver reproducibility. Gynecol Oncol 2006;100:544-50.
48. Feldman S, Berkowitz RS, Tosteson AN. Cost-effectiveness of strategies to evaluate postmenopausal bleeding. Obstet Gynecol 1993;81:968-75.
49. Dijkhuizen FP, Mol BW, Brölmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer 2000;89:1765-72.
50. Xie X, Lu WG, Ye DF, Chen HZ, Fu YF. The value of curettage in diagnosis of endometrial hyperplasia. Gynecol Oncol 2002;84:135-9. (Pubitemid 34056479)
51. Elsandabesee D, Greenwood P. The performance of Pipelle endometrial sampling in a dedicated postmenopausal bleeding clinic. J Obstet Gynaecol 2005; 25:32-4.
52. Arslan S, Aytan H, Gunyeli I, Koc O, Tuncay G, Tapisiz OL. Office hysteroscopic evaluation of endometrium: can we hit the target? Arch Gynecol Obstet 2005;271: 200-2.
53. Arslan S, Gökmen O, Tuncay G. The office hysteroscopic evaluation of postmenopausal patients. Arch Gynecol Obstet 2004;270:31-3. (Pubitemid 38915729)
54. Garuti G, Mirra M, Luerti M. Hysteroscopic view in atypical endometrial hyperplasias: A correlation with pathologic findings on hysterectomy specimens. J Minim Invasive Gynecol 2006;13:325-30.
55. Lasmar RB, Dias R, Barrozo PR, Oliveira MA, da Silva Freire Coutinho E, da Rosa DB. Prevalence of hysteroscopic findings and histologic diagnoses in patients with abnormal uterine bleeding. Fertil Steril 2008;89: 1803-7.
56. Lasmar RB, Barrozo PR, de Oliveira MA, Coutinho ES, Dias R. Validation of hysteroscopic view in cases of endometrial hyperplasia and cancer in patients with abnormal uterine bleeding. J Minim Invasive Gynecol 2006;13:409-12. (Pubitemid 44311676)
57. Clark TJ, Voit D, Gupta JK, Hyde C, Song F, Khan KS. Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia: a systematic quantitative review. JAMA 2002;288:1610-21.
58. Ceci O, Bettocchi S, Pellegrino A, Impedovo L, Di Venere R, Pansini N. Comparison of hysteroscopic and hysterectomy findings for assessing the diagnostic accuracy of office hysteroscopy. Fertil Steril 2002;78:628-31.
59. BenYO, KimYB, Leuchter RS. Does hysteroscopy improve upon the sensitivity of dilatation and curettage in the diagnosis of endometrial hyperplasia or carcinoma? Gynecol Oncol 1998;68:4-7.
60. Selvaggi L, Cormio G, Ceci O, Loverro G, Cazzolla A, Bettocchi S. Hysteroscopy does not increase the risk of microscopic extrauterine spread in endometrial carcinoma. Int J Gynecol Cancer 2003;13:223-7.
61. Clark, TJ, Neelakantan, D, Gupta, JK. The management of endometrial hyperplasia: an evaluation of current practice. Eur J Obstet Gynecol Reprod Biol 2006; 125:259.
62. Hecht JL, Ince TA, Baak JP, Baker HE, Ogden MW, Mutter GL. Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis. Mod Pathol 2005;18:324-30.
63. Marsden DE, Hacker NF. Optimal management of endometrial hyperplasia. Best Pract Res Clin Obstet Gynaecol 2001;15:393-405.
64. Lethaby A, Irvine G, Cameron I. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev 2000;(2):CD001016.
65. Lethaby A, Shepperd S, Cooke I, Farquhar C. Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding. Cochrane Database Syst Rev 2000;(2):CD000329.
66. Archer DF. The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women. Menopause 2001;8:245-51.
67. Ferenczy A, Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol 1989;160:126-31.
68. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma or the endometrium in women under age 40. Obstet Gynecol 1997;90:434-40.
69. Gal D. Hormonal therapy for lesions of the endometrium. Semin Oncol 1986;13(4 Suppl 4):33-6. (Pubitemid 17020172)
70. Lindahl B, Alm P, Fernö M, Killander D, Långström E, Norgren A, Tropé C. Prognostic value of steroid receptor concentration and flow cytometrical DNA measuremerrts in stage I-II endometrial carcinoma. Acta Oncol 1989;28:595-9.
71. Wildemeersch D, Dhont M. Treatment of nonatypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system. Am J Obstet Gynecol 2003;188:1297-8.
72. Pérez-Medina T, Bajo J, Folgueira G, Haya J, Ortega P. Atypical endometrial hyperplasia treatment with progestogens and gonadotropin-releasing hormone analogues: long-term follow-up. Gynecol Oncol 1999; 73:299-304. (Pubitemid 29215747)
73. Sedati A, Mariani L, Giovinazzi R, Yacoub M, Atlante G. The effectiveness of danazol therapy in postmenopausal women affected by endometrial hyperplasia. Clin Exp Obstet Gynecol 1992;19:161-5.
74. Grimbizis G, Tsalikis T, Tzioufa V, Kasapis M, Mantalenakis S. Regression of endometrial hyperplasia after treatment with the gonadotrophin-releasing hormone analogue triptorelin: a prospective study. Hum Reprod 1999;14:479-84.
75. Tamaoka Y, Orikasa H, Sumi Y, Sakakura K, Kamei K, Nagatani M et al. Direct effect of danazol on endometrial hyperplasia in adenomyotic women: treatment with danazol containing intrauterine device. Hum Cell 2000;13:127-33.
76. Järvelä I, Tekay A, Santala M, Jouppila P. Thermal balloon endometrial ablation therapy induces a rise in uterine blood flow impedance: a randomized prospective color Doppler study. Ultrasound Obstet Gynecol 2001;17:65-70.
77. Minassian VA, Mira JL. Balloon thermoablation in a woman with complex endometrial hyperplasia with atypia. A case report. J Reprod Med 2001;46:933-6.
78. Newfield RS, Spitz IM, Isacson C, New MI. Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia. Clin Endocrinol (Oxf) 2001;54:399-404.
79. Tabata T, Yamawaki T, Yabana T, Ida M, Nishimura K, Nose Y. Natural history of endometrial hyperplasia. Study of 77 patients. Arch Gynecol Obstet 2001;265:85-8.
80. Tabata T, Yamawaki T, Ida M, Nishimura K, Nose Y, Yabana T. Clinical value of dilatation and curettage for abnormal uterine bleeding. Arch Gynecol Obstet 2001;264:174-6.
81. Jacques SM, Qureshi F, Munkarah A, Lawrence WD. Interinstitutional surgical pathology review in gynecologic oncology: I. Cancer in endometrial curetting and biopsies. Int J Gynecol Pathol 1998;17:36-41.
82. Gimpelson RJ. Not so benign endometrial hyperplasia: endometrial cancer after endometrial ablation. J Am Assoc Gynecol Laparosc 1997;4:507-11.
83. Cianferoni L, Giannini A, Franchini M. Hysteroscopic resection of endometrial hyperplasia. J Am Assoc Gynecol Laparosc 1999;6:151-4.
84. Agorastos T, Vaitsi V, Pantazis K, Efstathiadis E, Vavilis D, Bontis N. Aromatase inhibitor anastrozole for treating endometrial hyperplasia in obese postmenopausal women. Eur J Obstet Gynecol Reprod Biol 2005;118:239-40. (Pubitemid 40093842)
85. Kistner RW. Histological effects of progestins on hyperplasia and carcinoma in situ of the endometrium. Cancer 1959;12:1106-22.
86. Casper RF. Regulation of estrogen/progestogen receptors in the endometrium. Int J Fertil Menopausal Stud 1996;41:16.
87. R Reed SD, Voigt LF, Newton KM, Garcia RH, Allison HK, Epplein M et al. Progestin therapy of complex endometrial hyperplasia with and without atypia. Obstet Gynecol 2009;113:655.
88. Lindahl B, Willen R. Spontaneous endometrial hyperplasia. A prospective, 5 year follow-up of 246 patients after abrasion only, including 380 patients followed-up for 2 years. Anticancer Res 1994;14:2141.
89. Affinito P, Di Carlo C, Di Mauro P, Napolitano V, Nappi C. Endometrial hyperplasia: efficacy of a new treatment with a vaginal cream containing natural micronized progesterone. Maturitas 1994;20:191-8.
90. Randall, TC, Kurman, RJ. Progestin treatment of atypical hyperplasia and well- differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997;90:434-40.
91. Wheeler DT, Bristow RE, Kurman RJ. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am J Surg Pathol 2007;31:988-98.
92. Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T et al. Multicenter phase II study of fertilitysparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 2007;25:2798-803.
93. Dhar KK, Needhirajan, T, Koslowski, M, Woolas RP. Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecol Oncol 2005;97:924-7.
94. Montz FJ, Bristow RE, Bovicelli A, Tomacruz R, Kurman RJ. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol 2002;186:651-7. (Pubitemid 34494341)
95. Agorastos T, Bontis J, Vakiani A, Vavilis D, Constantinidis T. Treatment of endometrial hyperplasias with gonadotropin-releasing hormone agonists: pathologic, clinical, morphometric, and DNA-cytometric data. Gynecol Oncol 1997;65:102-14.
96. Pérez-Medina T, Bajo J, Folgueira G, Haya J, Ortega P. Atypical endometrial hyperplasia treatment with progestogens and gonadotropin-releasing hormone analogues: long-term follow-up. Gynecol Oncol 1999;73: 299-304.
97. Mariani L, Sedati A, Giovinazzi R, Sindico R, Atlante G. Postmenopausal endometrial hyperplasia: role of danazol therapy. Int J Gynaecol Obstet 1994;44:155-9.
98. Bulletti C, Jasonni VM, Tabanelli S, Balducci M, Fuschini G, Flamigni C. Danazol reverses endometrial hyperplasia to normal endometrium. Acta Eur Fertil 1987;18:185-7.